Brii continues to grow infectious disease pipeline via deal with start-up AN2

Brii has added tuberculosis to its fast-growing infectious disease portfolio via a deal with start-up AN2, which emerged from stealth Thursday with a $12 million series A round.

Mountain Group Partners led the round with participation from Brii Biosciences, Adjuvant Capital and BioRock Ventures. ...